SYMPTOMATIC ANEMIA DURING CANCER CHEMOTHERAPY- rhERYTHROPIETIN (rhEPO) AND QUALITY OF LIFE
Author(s)
Bonicatto S, Giacomi N, Ferreras R, De la Cruz J, Cichetti G, Gelemur M, Riva M, Ivulich C, Ferreyra L, Fundaci n FUNDONAR, la Plata, Bosas, Argentina
In light of the current emphasis in the health care environment on both minimising cost and maximising favorable outcomes, it makes good economic sense to incorporate quality of life (QOL) assessment in order to sensitively evaluate the impact of interventions on individual s well being. The aim of the study was to determine to what extent QOL is influenced by the Hb increase and if, in this way, patients who showed improved Hb levels also showed improvements in QOL domains. 26 anemic cancer patients undergoing chemotherapy with initial Hb levels
Conference/Value in Health Info
2000-05, ISPOR 2000, Arlington, VA, USA
Value in Health, Vol. 3, No. 2 (March/April 2000)
Code
PCN11
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Oncology